BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1116 related articles for article (PubMed ID: 26810462)

  • 1. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
    Sierra M; Gelpi E; Martí MJ; Compta Y
    Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional Overlap of Pathologies in Lewy Body Disorders.
    Colom-Cadena M; Grau-Rivera O; Planellas L; Cerquera C; Morenas E; Helgueta S; Muñoz L; Kulisevsky J; Martí MJ; Tolosa E; Clarimon J; Lleó A; Gelpi E
    J Neuropathol Exp Neurol; 2017 Mar; 76(3):216-224. PubMed ID: 28395086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients.
    Daniele S; Baldacci F; Piccarducci R; Palermo G; Giampietri L; Manca ML; Pietrobono D; Frosini D; Nicoletti V; Tognoni G; Giorgi FS; Lo Gerfo A; Petrozzi L; Cavallini C; Franzoni F; Ceravolo R; Siciliano G; Trincavelli ML; Martini C; Bonuccelli U
    J Alzheimers Dis; 2021; 80(2):885-893. PubMed ID: 33579836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.
    Walker L; McAleese KE; Thomas AJ; Johnson M; Martin-Ruiz C; Parker C; Colloby SJ; Jellinger K; Attems J
    Acta Neuropathol; 2015 May; 129(5):729-48. PubMed ID: 25758940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia.
    Fujishiro H; Iseki E; Higashi S; Kasanuki K; Murayama N; Togo T; Katsuse O; Uchikado H; Aoki N; Kosaka K; Arai H; Sato K
    Neurosci Lett; 2010 Dec; 486(1):19-23. PubMed ID: 20851165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.
    Pletnikova O; West N; Lee MK; Rudow GL; Skolasky RL; Dawson TM; Marsh L; Troncoso JC
    Neurobiol Aging; 2005; 26(8):1183-92. PubMed ID: 15917102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.
    Coughlin D; Xie SX; Liang M; Williams A; Peterson C; Weintraub D; McMillan CT; Wolk DA; Akhtar RS; Hurtig HI; Branch Coslett H; Hamilton RH; Siderowf AD; Duda JE; Rascovsky K; Lee EB; Lee VM; Grossman M; Trojanowski JQ; Irwin DJ
    Ann Neurol; 2019 Feb; 85(2):259-271. PubMed ID: 30549331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.
    Arima K; Hirai S; Sunohara N; Aoto K; Izumiyama Y; Uéda K; Ikeda K; Kawai M
    Brain Res; 1999 Oct; 843(1-2):53-61. PubMed ID: 10528110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer's disease.
    Coughlin DG; Ittyerah R; Peterson C; Phillips JS; Miller S; Rascovsky K; Weintraub D; Siderowf AD; Duda JE; Hurtig HI; Wolk DA; McMillan CT; Yushkevich PA; Grossman M; Lee EB; Trojanowski JQ; Irwin DJ
    Neuropathol Appl Neurobiol; 2020 Dec; 46(7):707-721. PubMed ID: 32892355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying regional α -synuclein, amyloid β, and tau accumulation in lewy body dementia.
    Miller RL; Dhavale DD; O'Shea JY; Andruska KM; Liu J; Franklin EE; Buddhala C; Loftin SK; Cirrito JR; Perrin RJ; Cairns NJ; Campbell MC; Perlmutter JS; Kotzbauer PT
    Ann Clin Transl Neurol; 2022 Feb; 9(2):106-121. PubMed ID: 35060360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies.
    Obi K; Akiyama H; Kondo H; Shimomura Y; Hasegawa M; Iwatsubo T; Mizuno Y; Mochizuki H
    Exp Neurol; 2008 Apr; 210(2):409-20. PubMed ID: 18164295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Transforming Growth Factor β2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble Aβ42 Load.
    Chong JR; Chai YL; Lee JH; Howlett D; Attems J; Ballard CG; Aarsland D; Francis PT; Chen CP; Lai MK
    J Alzheimers Dis; 2017; 56(1):157-166. PubMed ID: 27911312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Mechanisms of the Roles of α-Synuclein, Amyloid-β, and Tau Protein in the Lewy Body Diseases: Pathogenesis, Early Detection, and Therapeutics.
    Noguchi-Shinohara M; Ono K
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders.
    Irwin DJ; Xie SX; Coughlin D; Nevler N; Akhtar RS; McMillan CT; Lee EB; Wolk DA; Weintraub D; Chen-Plotkin A; Duda JE; Spindler M; Siderowf A; Hurtig HI; Shaw LM; Grossman M; Trojanowski JQ
    Neurology; 2018 Mar; 90(12):e1038-e1046. PubMed ID: 29467305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders.
    Patterson L; Rushton SP; Attems J; Thomas AJ; Morris CM
    Brain Pathol; 2019 Jul; 29(4):544-557. PubMed ID: 30582885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies.
    Colom-Cadena M; Gelpi E; Charif S; Belbin O; Blesa R; Martí MJ; Clarimón J; Lleó A
    J Neuropathol Exp Neurol; 2013 Dec; 72(12):1203-12. PubMed ID: 24226269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
    Compta Y; Parkkinen L; O'Sullivan SS; Vandrovcova J; Holton JL; Collins C; Lashley T; Kallis C; Williams DR; de Silva R; Lees AJ; Revesz T
    Brain; 2011 May; 134(Pt 5):1493-1505. PubMed ID: 21596773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau pathology associates with in vivo cortical thinning in Lewy body disorders.
    Spotorno N; Coughlin DG; Olm CA; Wolk D; Vaishnavi SN; Shaw LM; Dahodwala N; Morley JF; Duda JE; Deik AF; Spindler MA; Chen-Plotkin A; Lee EB; Trojanowski JQ; McMillan CT; Weintraub D; Grossman M; Irwin DJ
    Ann Clin Transl Neurol; 2020 Dec; 7(12):2342-2355. PubMed ID: 33108692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline.
    Clinton LK; Blurton-Jones M; Myczek K; Trojanowski JQ; LaFerla FM
    J Neurosci; 2010 May; 30(21):7281-9. PubMed ID: 20505094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.